SCHEMBL31269308

SCHEMBL31269308

Cc1cnc(Cn2c(-c3ccc(OCCN4CCNCC4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)cc1C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.38
▸ HRH4 Q9H3N8 5/20 0.36
▸ DRD2 P14416 4/20 0.34
▸ SIGMAR1 Q99720 1/20 0.33
▸ ALK Q9UM73 1/20 0.32
▸ PRKAB2 O43741 1/20 0.32
▸ PRKAG1 P54619 1/20 0.32
▸ PRKAA2 P54646 1/20 0.32
▸ PRKAA1 Q13131 1/20 0.32
▸ PRKAG3 Q9UGI9 1/20 0.32
▸ PRKAG2 Q9UGJ0 1/20 0.32
▸ PRKAB1 Q9Y478 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ ESR1 P03372 3/20 0.31
▸ ESR2 Q92731 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269262 0.96 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983443 0.92 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269127 0.92 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983407 0.92 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269261 0.91 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30984048 0.91 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983467 0.91 PDE2A (0.38) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL31269151 0.90 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983551 0.90 PDE2A (0.37) PDE2AHRH4DRD2SIGMAR1ALK
SCHEMBL30983522 0.89 PDE2A (0.41) PDE2AHRH4DRD2ALKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback